Dyne Therapeutics (DYN)

• Market cap: $1.87B
• 1 day: -0.23%
• 5 days: -7.46%
• 1 month: 13.17%
• 3 months: -9.06%
• 6 months: 6.39%
• Year to date: -48.35%
• 1 year: -60.24%
• 5 years: -44.98%
• 10 years: -44.98%
• Sector: Healthcare
• Industry: Biotechnology

About: Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Employees: 206

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

83% more repeat investments, than reductions

Existing positions increased: 95 | Existing positions reduced: 52

20% more funds holding in top 10

Funds holding in top 10: 5 [Q1] → 6 (+1) [Q2]

5.39% more ownership

Funds ownership: 107.76% [Q1] → 113.15% (+5.39%) [Q2]

5% less capital invested

Capital invested by funds: $1.29B [Q1] → $1.23B (-$61.5M) [Q2]

4% less funds holding

Funds holding: 204 [Q1] → 196 (-8) [Q2]

23% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 30

53% less call options, than puts

Call options by funds: $390K | Put options by funds: $823K

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $9
• Avg. target: $30
• High target: $50

9 analyst ratings

• positive: 8 89%
• neutral: 1 11%
• negative: 0 0%

Raymond James Martin Auster	$35	Strong Buy Upgraded	25 Aug 2025
Oppenheimer Andreas Argyrides	$13	Outperform Maintained	6 Aug 2025
Stifel Paul Matteis	$36	Buy Maintained	31 Jul 2025
RBC Capital Luca Issi	$23	Outperform Maintained	29 Jul 2025
Chardan Capital Keay Nakae	$38	Buy Maintained	29 Jul 2025